Literature DB >> 7343319

Orgotein--(bovine Cu-Zn superoxide dismutase), an anti-inflammatory protein drug: discovery, toxicology and pharmacology.

W Huber.   

Abstract

Orgotein is the generic name adopted by the USAN Council for drug versions of the Cu-Zn superoxide dismutases. It is obtained from bovine liver by a process sequentially involving heat treatment, enzymatic digestion of other proteins and purification to homogeneity by molecular sieve and ion-exchange chromatography. Orgotein occurs naturally in all mammalian cells, with liver, kidney, and erythrocytes being the richest sources. Prior to employing Orgotein in the clinic, a variety of toxicological and pharmacological investigations in animals have been conducted. The results of these studies are being presented. They indicate that Orgotein possesses a potent anti-inflammatory activity coupled with a pronounced lack of general pharmacological effects, and that its toxicity is of an extremely low order. Orgotein, a major topic of this workshop, is the generic name adopted in 1971 by the U.S. Adopted Names Council for drug versions of the Cu-Zn superoxide dismutases (SOD).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7343319

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  9 in total

1.  The transcriptional activation of the human copper/zinc superoxide dismutase gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin through two different regulator sites, the antioxidant responsive element and xenobiotic responsive element.

Authors:  Eun Young Park; Hyune Mo Rho
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

Review 2.  Mechanisms of Normal Tissue Injury From Irradiation.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

Review 3.  Clinical pharmacokinetics and delivery of bovine superoxide dismutase.

Authors:  G Jadot; A Vaille; J Maldonado; P Vanelle
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

4.  2,6-Di-tert-butyl-4-(2'-thenoyl)phenol(R-830): a novel nonsteroidal anti-inflammatory agent with antioxidant properties.

Authors:  G G Moore; K F Swingle
Journal:  Agents Actions       Date:  1982-12

Review 5.  Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.

Authors:  Henry Jay Forman; Hongqiao Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-06-30       Impact factor: 84.694

6.  Exogenous superoxide dismutase: action on liver oxidative stress in animals with streptozotocin-induced diabetes.

Authors:  Fábio Cangeri Di Naso; Alexandre Simões Dias; Marilene Porawski; Norma Anair Possa Marroni
Journal:  Exp Diabetes Res       Date:  2011-03-13

7.  Therapeutic evaluation of HIV transduction basic domain-conjugated superoxide dismutase solution on suppressive effects of the formation of peroxynitrite and expression of COX-2 in murine skin.

Authors:  Tsang-Pai Liu; Yi-Ping Chen; Chih-Ming Chou; Ting-Ting Chiu; Chien-Tsu Chen
Journal:  J Biomed Sci       Date:  2016-01-20       Impact factor: 8.410

Review 8.  Biology of Radiation-Induced Lung Injury.

Authors:  Soumyajit Roy; Kilian E Salerno; Deborah E Citrin
Journal:  Semin Radiat Oncol       Date:  2021-04       Impact factor: 5.934

9.  Biomarkers of antioxidant status, inflammation, and cartilage metabolism are affected by acute intense exercise but not superoxide dismutase supplementation in horses.

Authors:  Emily D Lamprecht; Carey A Williams
Journal:  Oxid Med Cell Longev       Date:  2012-08-08       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.